ahlam1399
07-18-2016, 02:18 PM
BRIEF-Genentech says phase III study evaluating Gazyva did **t meet primary endpoint
* Genentech provides update on phase III study of Gazyva inpeople with previously untreated diffuse large b-cell lymphomahttp://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=FGGAYLfS4IM:PtRySoYfKso:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=FGGAYLfS4IM:PtRySoYfKso:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=FGGAYLfS4IM:PtRySoYfKso:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=FGGAYLfS4IM:PtRySoYfKso:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=FGGAYLfS4IM:PtRySoYfKso:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/FGGAYLfS4IM
* Genentech provides update on phase III study of Gazyva inpeople with previously untreated diffuse large b-cell lymphomahttp://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=FGGAYLfS4IM:PtRySoYfKso:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=FGGAYLfS4IM:PtRySoYfKso:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=FGGAYLfS4IM:PtRySoYfKso:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=FGGAYLfS4IM:PtRySoYfKso:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=FGGAYLfS4IM:PtRySoYfKso:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/FGGAYLfS4IM